Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients

By on    Pharma Industry News  

Suven Life Sciences begins Masupirdine phase 3 clinical trial in dementia patients

Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer’s type by randomizing the first patient. According to the Indian biopharma company, the late-stage trial of the serotonin-6 (5-HT6) receptor antagonist is a double-blind, placebo-controlled study intended to be held in 50 sites in North America and […]

Suven Life Sciences to launch phase 3 clinical trial for Masupirdine

By on    Pharma Industry News  

Suven Life Sciences to launch phase 3 clinical trial for Masupirdine

Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias. The Indian biopharma company expects to enroll patients from mid-September. Masupirdine is a selective, brain penetrant and orally active, chemical entity. Its late-stage study to be […]